Nilsson O, Johansson C, Glimelius B, Persson B, Nørgaard-Pedersen B, Andrén-Sandberg A, Lindholm L
Pharmacia CanAg, Göteborg, Sweden.
Br J Cancer. 1992 Feb;65(2):215-21. doi: 10.1038/bjc.1992.44.
A serological assay for the quantitative determination of the novel tumour-associated epitope CA242 was developed and used for determination of sensitivity and specificity of CA242 in gastrointestinal cancer. The CA242 assay showed a better tumour specificity than CA50 (and CA 19-9). This was most noticeable in benign hepatobiliary disease. The sensitivity at 90% specificity cut-off level was approximately three times higher for CA242 compared to CA50 in colo-rectal cancer Dukes A, B and C, while in pancreatic cancer the sensitivity of CA242 and CA50 was similar. CA242 was expressed independently of CEA, and the combination of CEA and CA242 gave in colo-rectal cancer considerably higher sensitivity than the use of only one of the markers. This was most pronounced in Dukes A and Dukes B patients. CA242 is a novel tumour marker of potential clinical use, particularly in colo-rectal cancer.
开发了一种用于定量测定新型肿瘤相关表位CA242的血清学检测方法，并用于测定CA242在胃肠道癌中的敏感性和特异性。CA242检测显示出比CA50（和CA19-9）更好的肿瘤特异性。这在良性肝胆疾病中最为明显。在结直肠癌Dukes A、B和C期，与CA50相比，CA242在90%特异性临界值水平时的敏感性约高3倍，而在胰腺癌中，CA242和CA50的敏感性相似。CA242的表达独立于CEA，在结直肠癌中，CEA和CA242联合使用的敏感性比仅使用其中一种标志物要高得多。这在Dukes A期和Dukes B期患者中最为明显。CA242是一种具有潜在临床应用价值的新型肿瘤标志物，尤其在结直肠癌中。
